Ars Technica OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.
The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.